Given Imaging to Host First Quarter 2013 Financial Results Conference Call on May 9, 2013

Given Imaging to Host First Quarter 2013 Financial Results Conference Call on
May 9, 2013

YOQNEAM, Israel, April 24, 2013 (GLOBE NEWSWIRE) -- Given Imaging
(Nasdaq:GIVN) today announced that the company will host a conference call on
Thursday, May 9, 2013 at 9:00am ET, 4:00pm Israel time to discuss first
quarter 2013 financial results. The company plans to release results following
the close of U.S. financial markets on Wednesday, May 8, 2013.

To participate in the teleconference, please dial the following numbers
fifteen minutes before the call is scheduled to begin: U.S. and Canada,
888-438-5491; Israel, 1-80-924-5906. Callers in other countries should dial
719-785-1753. The call will also be webcast live at

A replay of the call will be available for two weeks on the company's website,
or until May 23, 2013, by dialing 888-203-1112. Callers in Israel should dial
1-80-924-6038. Callers outside of the U.S. and Israel should dial
719-457-0820. The replay participant code is 3944471.

About Given Imaging Ltd.

Since pioneering the field of capsule endoscopy in 2001, Given Imaging has
become a world leader in GI medical devices, offering health care providers a
range of innovative options for visualizing, diagnosing and monitoring the
digestive system. The company offers a broad product portfolio including
PillCam® capsule endoscope for the small bowel, esophagus and colon. The
company also offers industry-leading GI functional diagnostic solutions
including ManoScan™ high-resolution manometry, Bravo® capsule-based pH
monitoring, Digitrapper® pH-Z impedance, and the SmartPill® GI monitoring
systems. Given Imaging is committed to delivering breakthrough innovations to
the GI community and supporting its ongoing clinical needs. Given Imaging's
headquarters are located in Yoqneam, Israel, with operating subsidiaries in
the United States, Germany, France, Japan, Australia, Vietnam, Hong Kong and
Brazil. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not limited to,
projections about our business and our future revenues, expenses and
profitability. Forward-looking statements may be, but are not necessarily,
identified by the use of forward-looking terminology such as "may,"
"anticipates," "estimates," "expects," "intends," "plans," "believes," and
words and terms of similar substance. Forward-looking statements involve known
and unknown risks, uncertainties and other factors which may cause the actual
events, results, performance, circumstances or achievements of the Company to
be materially different from any future events, results, performance,
circumstances or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements include statements relating to the
Company exploring strategic alternatives and considering possible strategic
transactions involving the Company. Factors that could cause actual events,
results, performance, circumstances or achievements to differ from such
forward-looking statements include, but are not limited to, the ability of the
Company to reach agreement on any strategic alternative and/or to complete any
such alternative, as well as the following: (1) our ability to develop and
bring to market new products, (2) our ability to successfully complete any
necessary or required clinical studies with our products, (3) our ability to
receive regulatory clearance or approval to market our products or changes in
regulatory environment, (4) our success in implementing our sales, marketing
and manufacturing plans, (5) the level of adoption of our products by medical
practitioners, (6) the emergence of other products that may make our products
obsolete, (7) lack of an appropriate bowel preparation materials to be used
with our PillCam COLON capsule, (8) protection and validity of patents and
other intellectual property rights, (9) the impact of currency exchange rates,
(10) the effect of competition by other companies, (11) the outcome of
significant litigation, (12) our ability to obtain reimbursement for our
product from government and commercial payors, (13) quarterly variations in
operating results, (14) the possibility of armed conflict or civil or military
unrest in Israel, (15) the impact of global economic conditions, (16) our
ability to successfully integrate acquired businesses, (17) changes and
reforms in applicable healthcare laws and regulations, (18) quality issues and
adverse events related to our products, such as capsule retention, aspiration
and failure to attach or detach, bleeding or perforation that could require us
to recall products and impact our sales and net income, and (19) other risks
and factors disclosed in our filings with the U.S. Securities and Exchange
Commission, including, but not limited to, risks and factors identified under
such headings as "Risk Factors," "Cautionary Language Regarding
Forward-Looking Statements" and "Operating Results and Financial Review and
Prospects" in the Company's Annual Report on Form 20-F for the year ended
December 31, 2012. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. Except to the extent expressly required under applicable law, the
Company undertakes no obligation to release publicly any revisions to any
forward-looking statements, to report events or to report the occurrence of
unanticipated events.

CONTACT: Fern Lazar/David Carey
         Lazar Partners Ltd.
         212 867 1768
         Israel Investor Contact:
         Nava Ladin
         Gelbart Kahana Investor Relations
Press spacebar to pause and continue. Press esc to stop.